Short answer
Gilead Sciences (GILD) filed its Q1 2025 10-Q quarterly report on May 7, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $6.7B (down 0.3% year over year) with net income of $1.3B.
Q1 2025 key financials · XBRL
- Revenue
- $6.7B
- −0.3% YoY
- Net income
- $1.3B
- +131.5% YoY
- Operating margin
- 33.6%
- EPS (diluted)
- $1.04
- +131.1% YoY
Source: XBRL data from the Gilead Sciences (GILD) Q1 2025 10-Q on SEC EDGAR. USD.
Gilead Sciences Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA boxed warning on CAR T therapies for secondary T-cell malignancies effective January 2024
- Updated product commercialization risk: Phase 3 EVOKE-01 trial failed in January 2024, causing impairment charge impacting pipeline valuation
- Regulatory pricing risk: IRA implementation increases rebates, discounts, and Medicare Part D liabilities beginning 2023-2025, reducing profitability
- Operational risk: dependency on third-party apheresis centers and logistics for CAR T-cell therapies risks product loss and manufacturing delays
- Financial risk: ~90% U.S. sales concentrated in 3 wholesalers, causing potential revenue fluctuations due to inventory mismatches
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.